12399456https://www.upal.com.my/zh/feeds/jobFeedKwongwahArray ( [0] => HTTP/1.1 200 OK [1] => Date: Sun, 23 Nov 2025 18:11:14 GMT [2] => Content-Type: text/xml; charset=utf-8 [3] => Connection: close [4] => Cache-Control: no-cache, private [5] => Cache-Control: no-cache, no-store, must-revalidate [6] => Nel: {"report_to":"cf-nel","success_fraction":0.0,"max_age":604800} [7] => x-frame-options: SAMEORIGIN [8] => x-content-type-options: nosniff [9] => x-xss-protection: 1; mode=block [10] => referrer-policy: strict-origin-when-cross-origin [11] => permissions-policy: geolocation=(), microphone=(), camera=() [12] => content-security-policy: default-src * 'unsafe-inline' 'unsafe-eval' data: blob:; script-src * 'unsafe-inline' 'unsafe-eval' data: blob:; style-src * 'unsafe-inline' data:; img-src * data: blob:; font-src * data:; connect-src *; frame-src *; object-src *; media-src *; child-src *; [13] => Server: cloudflare [14] => x-robots-tag: noindex, nofollow, nosnippet, noarchive [15] => strict-transport-security: max-age=31536000; includeSubDomains; preload [16] => expires: Mon, 24 Nov 2025 18:11:14 GMT [17] => vary: Accept-Encoding [18] => Report-To: {"group":"cf-nel","max_age":604800,"endpoints":[{"url":"https://a.nel.cloudflare.com/report/v4?s=pOEZR%2Bk%2FB6nzQ2LXUNusktxmpfGv8xSmmwuIbx6tVXhP%2Fuh0b1fj%2BuCLv1eScHCUj65lRBqAU4Z%2BEWT8HdATXa8CwOK9fg%2FcmwT14eY%3D"}]} [19] => cf-cache-status: DYNAMIC [20] => Speculation-Rules: "/cdn-cgi/speculation" [21] => Server-Timing: cfCacheStatus;desc="DYNAMIC" [22] => Server-Timing: cfEdge;dur=2,cfOrigin;dur=102 [23] => Set-Cookie: UpalLiveSession=eyJpdiI6InN3Rm5YZjlyZVR3dVVaN2I4UFFFc2c9PSIsInZhbHVlIjoiQldEclNGZXQ1Q3k1UEJEYXRlUFM5SkVZSGt2NENUaDhjU1czRGVUSmMzYlwvNlVnOFhLWWJncTV2Sk14Y09nZU05eGZcL0RoNzJ2ZGpVVW53T3gyckpDdz09IiwibWFjIjoiYWEyODJiOTgzODdmZWM2MTc5NDMxM2Q5MDU0MTE0ZTBjYzA3ZjcyYzZiZTVjZmNlY2JjMmIzMzdhZmYyY2E5ZCJ9; HttpOnly; Path=/; Max-Age=94608000; Expires=Wed, 22 Nov 2028 18:11:14 GMT [24] => CF-RAY: 9a32a0bcfcddcf0c-KUL [25] => alt-svc: h3=":443"; ma=86400 ) 789

针对新加坡科学局宣布召回3种含有超标致癌物质的药物二甲双胍（metformin），我国卫生部周四发文告强调，我国并没批准发售这3种药物。

这3种药物包括Glucient XR Tablet 500mg、Meijumet Prolonged Release Tablet 750mg，以及Meijumet Prolonged Release Tablet 1000mg；有关药物是控制血糖的药物。

卫生总监拿督诺希山周四在文告中指出，卫生部对国家药品监管局（NPRA）注册的药物进行审查后发现，美国药物管制局共检验101项药物含有二甲双胍成份，然而只有获得注册的药物才获准在我国发售。

文告指，NDMA是亚硝胺基的杂质之一，通常含量较低。“根据国际癌症研究机构（IARC）显示，长期服用NDMA将增加患癌风险。”

“二甲双胍是一种治疗糖尿病以控制血糖的药物，平时可从医生或药剂师处获取。”

无论如何，国家药品监管局将继续监视市面上的药物，确保药物的质量、安全和有效性，并随时提醒民众。